• Adjusting To GDPR, One Year Later

    Clinical Research News | A year out from the regulation's launch, Mariya Pinskaya, Principal Consultant at Areva Consulting, sees a very consistent experience for trial participants, even if study teams are working harder in the background.

    Jun 20, 2019

  • SCOPE Europe Returns To Spain

    Clinical Research News | SCOPE, the Summit for Clinical Ops Executives, is heading back to Barcelona for a deep dive into the challenges and opportunities for clinical research in Europe and beyond.

    Jun 18, 2019

  • TrialAssure's New Web Portal Shares Trial Results In Plain Language

    Clinical Research News | TrialAssure recently launched TrialResults.com, a web portal for clinical trial sponsors to publicly share plain language, or lay, summaries with clinical trial participants.

    Jun 14, 2019

  • Dassault Systèmes Acquires Medidata Solutions For $5.8 Billion

    Clinical Research News | Dassault Systèmes announced this morning that it is acquiring Medidata Solutions at a price of $92.25 per share, representing an enterprise value of $5.8 billion.

    Jun 12, 2019

  • Greenphire Forms Strategic Partnership With Lazarex Cancer Foundation

    Clinical Research News Brief | Greenphire recently announced that it has formed a partnership with the Lazarex Cancer Foundation, which will implement Greenphire's ClinCard participant reimbursement technology to remove financial burdens for the oncology patients it supports across the United States.

    Jun 11, 2019

  • CRF Bracket Relaunches As Signant Health

    Clinical Research News | CRF Bracket announced a new name and brand today. The company will now be known as Signant Health, a name more indicative of the kind of business the company is trying to build.

    Jun 10, 2019

  • Why Pfizer Didn't Report Its Rheumatoid Arthritis Medication Might Prevent Alzheimer's

    The Washington Post | A team of researchers inside Pfizer found the company's blockbuster rheumatoid arthritis therapy Enbrel, a powerful anti-inflammatory drug, appeared to reduce the risk of Alzheimer's disease by 64%. However, Pfizer opted against further investigation and chose not to make the data public, the company confirmed.

    Jun 5, 2019